Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 7/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927566 | 1.00 | FFAR4 (0.36) | FFAR4ALOX5FPR2SPHK1GABRA1 | |
| SCHEMBL12023648 | 0.88 | ALOX5 (0.37) | FFAR4ALOX5FPR2SPHK1KDM1A | |
| SCHEMBL12023523 | 0.88 | FPR2 (0.34) | FFAR4ALOX5FPR2KDM1A | |
| SCHEMBL9927554 | 0.86 | FPR2 (0.33) | FFAR4ALOX5FPR2KDM1A | |
| SCHEMBL9927704 | 0.85 | ALOX5 (0.33) | FFAR4ALOX5SPHK1S1PR1 | |
| SCHEMBL12759388 | 0.83 | ALOX5 (0.45) | ALOX5SPHK1KDM1A | |
| SCHEMBL18718221 | 0.82 | ALOX5 (0.39) | FFAR4ALOX5FPR2KDM1A | |
| SCHEMBL9927613 | 0.82 | FPR2 (0.35) | FPR2 | |
| SCHEMBL9927581 | 0.82 | FPR2 (0.35) | FPR2SPHK1 | |
| SCHEMBL9927571 | 0.81 | SPHK1 (0.38) | FPR2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468740-B1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2468740-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| WO-2011021534-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | チッソ株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CCND1, CCND2 | FFAR4 1322/4885ALOX5 2655/4885FPR2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.